The purpose of this review is to highlight some of the advances in the way we think about rhabdomyosarcoma (RMS). Recent outcome and biological analyses have shifted the risk stratification and treatment paradigms for pediatric RMS.
INTRODUCTION
Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children, comprising 2.9% of all pediatric cancers with an annual incidence in the United States of 4.3 per million children less than 20 years. There are two broad RMS histologic subtypes: embryonal (ERMS) and alveolar (ARMS). Treatment has evolved significantly over the past 50 years to include intensive, multiagent chemotherapy [most commonly vincristine, dactinomycin, and cyclophosphamide (VAC) in North America] for all patients, radiation therapy for most, and surgical resection for some. Although survival rates improved dramatically from 1960 to 1996, there has been little change in more recent years. To adjust the intensity of therapy to the probability of recurrence, treatment is guided by a risk stratification based on pretreatment histology, site of primary tumor, the extent of residual tumor after surgery, and presence of distant metastases to define three distinct RMS risk groups: low-risk, intermediate-risk, and high-risk (Table 1) . Recent Children's Oncology Group (COG) clinical trials have attempted to reduce the short-term and long-term toxicity of therapy for low-risk RMS and improve the survival for intermediate-and high-risk RMS.
In this review, we describe novel aspects of biology, diagnosis, risk stratification, staging, and therapy of pediatric RMS. The identification of the prognostic value of the FOXO1 (previously referred to as FKHR) translocation status in RMS is one of the most important shifts in the risk stratification of this disease, which will be incorporated in all future studies. Genomic analyses have identified several recurring somatic alterations, including some that are potential therapeutic targets. Although recent large clinical trials show no overall improvement in outcome of patients with RMS, important lessons have been confirmed regarding the value of radiotherapy and the specific situations in which reduction of treatment intensity would be safe
PROGNOSTIC SUBGROUPS OF ALVEOLAR RHABDOMYOSARCOMA
Fusion of the PAX3 or PAX7 genes on chromosome 2 or 1, respectively, with the FOXO1 gene on chromosome 13 is seen in the vast majority of ARMS. 
BASIC SCIENCE ADVANCES
The cell of origin for RMS remains unknown. It is thought that ERMS develops from muscle KEY POINTS FOXO1 fusion status is more closely associated with outcome than histologic classification and will be used in future clinical trials for risk stratification.
In FOXO1 fusion-positive RMS, abnormalities of ALK are common, whereas RAS, Hh, p53, NF1, PIK3CA, and b-catenin are more common in FOXO1 fusionnegative RMS.
FDG-PET may be more sensitive to detect metastatic disease (particularly in lymph nodes) and may be useful to evaluate response to therapy.
Recent chemotherapy clinical trials have failed to show improved outcome despite the incorporation of additional agents.
Radiation therapy remains essential to optimize the probability of cure, although balancing effective cancer therapy with the late effects of local treatment is a challenge. progenitor cells, given the similar expression of skeletal muscle markers in both cell types. The development of ERMS at sites that lack striated muscle, such as the bladder, prostate, and biliary tree, remains unexplained. Several studies have provided new insights into the genetic origin of RMS. Hatley et al. [13] developed a mouse model of ERMS originating from an adipocyte lineage through adipocyte-restricted activation of the hedgehog (Hh) pathway by an oncogenic Smoothened allele. This model may account for ERMS at sites that normally lack skeletal muscle, and suggests that ERMS may arise through transdifferentiation of mesenchymal, nonskeletal muscle precursors. In contrast, Rubin et al. [14] developed mouse models of RMS using p53 and Ptch1 mutations in muscle stem cells and proliferating and mature myoblasts. RMS developed from all subpopulations of muscle cells, although the mutational profile and cell of origin were important in determining the proportion of tumors with an RMS versus undifferentiated pleomorphic/spindle cell sarcoma (UPS) phenotype. Maturing myoblasts gave rise to more ERMS, whereas UPS were more likely to evolve from PAX7-expressing satellite cells (muscle stem cells). Additionally, Rb1 expression modified the tumor phenotype to mimic UPS. These results suggest that a continuum exists between ERMS and UPS, and that at least a subset of ERMS and UPS share a common myogenic cell(s) of origin.
Tapscott et al. have examined the role of epigenetic modifications in the development of RMS [15 && ,16] , proposing that RMS cells represent an arrested state of development of normal skeletal muscle, with regional and local silencing of differentiation factors contributing to the maturation defect in RMS. Additionally, they showed that genome-wide DNA methylation patterns can distinguish RMS subtypes, suggesting aberrant DNA methylation silences genes important for the pathogenesis of RMS.
Other groups have also examined the mechanism of failure of myogenic differentiation in RMS. Jothi and Mal [17] demonstrated that AKT regulation of the PAX3-FOXO1 fusion protein suppresses myogenic gene expression in ARMS cells, causing a failure in differentiation. Hosoyama et al. [18] examined the role of interleukin-4 receptor (IL-4R), which is important for the maturation of myotubes. Stimulation of IL-4R signaling in RMS enhanced tumor cell proliferation, whereas inhibition of this pathway decreased cell proliferation but not apoptosis. IL-4R blockade may, therefore, be used therapeutically to modulate the expression of myogenic transcription factors (MyoD or myogenin).
TRANSLATIONAL RESEARCH
Aberrant activation of cell signaling pathways resulting in therapeutically relevant mutations allows novel treatment options in many tumors, including RMS (Table 2) . Pressey et al. [19] showed that a substantial subset of ERMS and undifferentiated sarcomas show activation of the Hh pathway. This was confirmed by array comparative genomic hybridization (aCGH) studies, which showed that over 50% of ERMS tumors had activation of the Hh-pathway transcription factor GLI1 [20] . CGH data also showed inactivation of p53 and Rb pathways, CDKN2A/B, and activation of FGFR4 and Ras in varying subsets of ERMS tumors. Intragenic deletions of NF1, a tumor suppressor and inhibitor of Ras, were mutually exclusive from activating Ras mutations, suggesting that NF1 loss may be an alternative mechanism of Ras activation in ERMS [20] . Using targeted sequencing for common cancer-associated mutations, Shukla et al. [21 && ] also [23] or late in the treatment plan [24] fails to predict disease recurrence. A single institutional review demonstrated that patients who had a negative PET following induction chemotherapy and radiotherapy had a better local relapse-free survival than patients with a positive PET (94 versus 75%, P ¼ 0.02) [25 && ]. In the future, FDG-PET might replace conventional staging imaging studies, particularly for lymph node disease [26 & ,27] . Routine staging evaluation, including bone marrow aspiration/biopsy and bone scans, is unnecessary in one-third of ERMS, and CT chest could be omitted in patients with node-negative, noninvasive disease [28 & ].
TOXICITY OF CHEMOTHERAPY: INDIVIDUALIZED CARE
VAC has been the North American standard treatment for RMS for more than four decades [1
& ]. However, increasing attention is being devoted to the understanding of age-related dosing and chemotherapy toxicities and outcome. Patients less than 1 or more than 10 years fare worse than those aged 1-10 years [29,30 & ,31] . Patients less than 1 year of age had increased rates of hepatopathy on COG D9803, which led to dose reductions in VAC for infants [32] . Despite dose reductions, the significantly increased rates of toxicity to VAC in children less than 1 year of age were confirmed in a multistudy analysis performed on 4567 patients [33] .
Furthermore, risk of toxicity with dactinomycin does not correlate with increasing cumulative exposure to the drug (dose or time) suggesting that toxicity may be related to specific susceptibility. Adolescents experience significantly less hematologic toxicity compared with younger children despite receiving comparable cumulative chemotherapy doses in one study of intermediate-risk RMS [34 & ]. Therefore, dose modifications in response to toxicity do not explain the age-related difference in outcome. Rather, the lower degree of hematologic toxicity observed in adolescents may reflect relatively lower systemic exposure to chemotherapy.
The impact of BMI on toxicity and outcome in RMS has also been explored [35] . Patients with low BMI (<5%ile), or those who lose significant weight experience greater toxicity than other children. Patients with low BMI may also have inferior survival. Whether this effect is influenced by patient age remains unknown. Future studies may consider early and more aggressive nutritional interventions to minimize toxicity.
RECENT TRIALS IN RHABDOMYOSARCOMA: REDUCTION IN DOSE INTENSITY
COG D9803 randomized patients with intermediaterisk RMS to VAC versus VAC alternating with vincristine, topotecan and cyclophosphamide (VTC). A total of 617 eligible patients were entered onto the study and, at a median follow-up of 4.3 years, 4-year failure-free survival (FFS) was 73% with VAC and 68% with VAC/VTC (P ¼ 0.3) [36] . The outcome between the two arms was similar despite a 20% decrease in the total dose of cyclophosphamide in the VAC/VTC arm (30.8 compared with 25.1 g/m 2 ). Concurrently with COG D9803, COG D9602 tested reductions in treatment in low-risk RMS [37] . In this study, subgroup A patients (lowest risk, with ERMS, stage 1 group I/IIA, stage 1 group III orbit, stage 2 group I) received VAC, and subgroup B patients (ERMS, stage 1 group IIB/C, stage I group III nonorbit, stage 2 group II, stage 3 group I/II) received VAC (13 cycles of VAC, total dose of cyclophosphamide ¼ 28.6 g/m 2 ) [37] . The complete elimination of cyclophosphamide in subgroup A resulted in an inferior 5-year FFS of 81 compared with 85% on Intergroup Rhabdomyosarcoma Study IV (IRS-IV). Patients in subgroup B had a 5-year FFS of 85%.
Vaginal primary site ERMS illustrate the challenge of balancing effective local treatment with long-term morbidity. The most recent COG low-risk RMS study, ARST0331, treated vaginal primary ERMS with a low cumulative dose of cyclophosphamide (4.8g/m2) and a local control strategy designed to minimize radiation and extensive surgery. The 5-year cumulative incidence of local recurrence was 43% on ARST0331, compared with 26% on COG D9602 with higher-dose cyclophosphamide [38] . The omission of radiation therapy was the most likely cause for the high rate of local failures, although lower cyclophosphamide dose may have contributed.
The International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor (MMT) group compared standard versus intensive chemotherapy in patients with high-risk nonmetastatic RMS (MMT 95) [39 && ]. After one course of ifosfamide, vincristine, and dactinomycin (IVA), 385 patients with RMS were randomly assigned to IVA or IVA alternating with carboplatin, etoposide, and vincristine (CEV) and ifosfamide, vincristine, and etoposide (IVE). Intensifying chemotherapy did not improve survival or reduce the intensity of local therapy, but was associated with increased toxicity.
OPTIMIZING DOSE AND DELIVERY OF RADIOTHERAPY
Several factors drive the desire to reduce or omit radiation therapy in the treatment of RMS: low-risk RMS has a favorable outcome; there is increasing awareness of late effects of radiation therapy; and RMS is very radiosensitive. Reduction in the dose of radiation from 41.4 to 36 Gy for marginally resected ERMS and from 50.4 to 45 Gy for orbital ERMS did not compromise outcome on COG D9602 [40 & ]. Very young children or patients with pelvic primary sites are particular candidates for omission of radiation therapy due to the profound impact on growth. However, omission of radiation therapy results in a higher recurrence rate, necessitating more aggressive second-line therapy and potentially compromising overall survival. SIOP MMT, CWS, and the Italian Cooperative Group (ICG) have incorporated response to chemotherapy and conservative surgery to omit radiation therapy whenever possible. An international analysis of bladder/ prostate ERMS showed this strategy resulted in a slightly higher relapse risk, but similar overall survival compared with the COG strategy [41] .
COG recently analyzed noncompliance with radiation therapy among nearly 700 RMS patients who had postoperative microscopic residual disease (Group II) [42] . The majority of operative bed recurrences were associated with omission of radiation therapy. The COG analysis differs from prior SIOP MMT and CWS reports by including more non-ERMS and all primary tumor sites. Infants with RMS have a higher rate of disease recurrence than older children, in part due to the compromise in radiation therapy delivery and consequent local failures [31] . Thus, the late toxicity from radiation therapy needs to be balanced with the risk of failure; although these decisions continue to be difficult for physicians and families, data continue to support the need for radiation therapy to optimize cure in most patients with RMS.
There have also been evolutions in the modality of radiation therapy used to treat patients with pediatric RMS. Intensity-modulated radiation therapy (IMRT) offers the potential to provide improved target coverage and a lower radiation dose to the surrounding critical organs compared with three-dimensional conformal radiation therapy (3D-CRT). In COG D9803, the technique of radiation therapy varied by treating institution; sufficient dosimetric data on 179 patients were available for analysis [43 & ]. There was no difference in 5-year FFS; however, in patients with primary parameningeal tumors, toxicity (dermatitis, thrombocytopenia) was less in those who received IMRT compared with those who received 3D-CRT.
RE-THINKING LYMPH NODE DISEASE
Patients with RMS are at high risk for presenting with regional lymph node disease (N1), and subsequent nodal failure if not adequately treated. Nodal disease is an independent prognostic marker, especially in ARMS and extremity primary sites. On IRS-IV, 23% of patients were N1 at presentation, which was an independent prognostic factor in ARMS [44] . N1 status was more common in older patients, those with ARMS, large tumors, and tumors at certain anatomic sites (including perineum, retroperitoneum, extremity, bladder/prostate, parameningeal, and paratesticular). Two primary sites deserve surgical lymph node staging: extremity and paratesticular in patients more than 10 years old. A recent analysis of the Surveillance, Epidemiology, and End Results database demonstrated that 40% of patients more than 10 years of age with paratesticular RMS had N1 disease. Among these older patients, the 5-year survival was better for those patients who underwent lymph node dissection than those who did not (92 versus 76%, P ¼ 0.028) [45 && ]. Furthermore, the addition of radiation therapy improved the 5-year survival in N1 patients (90 versus 36%; P <0.0001), but made no difference to those with N0 disease. These data support routine retroperitoneal lymph node sampling in patients aged more than 10 years and regional lymph node radiation in N1 patients.
CONCLUSION
FOXO1 fusion status will replace histologic classification for risk stratification in future RMS clinical trials. Comprehensive genomic analysis and mouse models of RMS provide novel insights into the etiology of RMS and potential therapeutic targets. Recent randomized chemotherapy trials have failed to improve outcome despite the introduction of newer or more intensive therapy. Future clinical trials will refine the use of radiation therapy, particularly in the youngest children. 
